Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated claim(s) are fully supported by the provided DUAVEE FDA label excerpts, including the boxed warning statements regarding endometrial cancer, cardiovascular disorders (stroke and VTE/DVT), probable dementia, and the explicit limitation against prevention of cardiovascular disease or dementia.
Category Scores
Accurate Statements
DUAVEE use is associated with risks of endometrial cancer.
Boxed Warning: ENDOMETRIAL CANCER...; Section 5.3 Malignant Neoplasms (Endometrial Cancer).
DUAVEE use is associated with risks of cardiovascular disorders, including stroke and VTE.
Boxed Warning; Section 5.2 Cardiovascular Disorders (reports increased risk of stroke and DVT/VTE with estrogen-alone therapy; bazedoxifene/estrogen agonist/antagonist component noted).
DUAVEE use is associated with risks of probable dementia.
Boxed Warning; Section 5.4 Probable Dementia (increased risk in WHIMS estrogen-alone ancillary study).
DUAVEE should not be used for the prevention of cardiovascular disease or dementia.
Boxed Warning: 'Estrogen therapy should not be used for the prevention of cardiovascular disease or dementia'.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim accurately reflects boxed warning risks and the labeled limitation of use; no incorrect safety statements were identified relative to the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement